Stifel Initiates TRex Bio Coverage With Buy Rating, $39 Target
Stifel Nicolaus initiated coverage of TRex Bio with a Buy rating and a $39 price target.
Related stories
Bowhead Specialty Holdings Reports Quarterly Results
The headline reports results for the quarter ended September 30. The body provides no figures or further results details.
M impact | EQUITY | Nov 03, 2026, 02:33 PM UTC
Revvity Reports Quarterly Results for Period Ended September 30
The headline provides no revenue, profit, EPS or other result figures.
M impact | EQUITY | Nov 03, 2026, 02:33 PM UTC
Vital Farms Reports Quarterly Results for Quarter Ended September 30
M impact | EQUITY | Nov 03, 2026, 02:33 PM UTC
Xenia Hotels & Resorts Reports Quarterly Results
Xenia Hotels & Resorts reported results for the quarter ended September 30. The supplied text does not include the figures.
M impact | EQUITY | Nov 03, 2026, 02:32 PM UTC
Regal Rexnord Reports Quarterly Results Through September 30
Regal Rexnord Corporation reported results for the quarter ended September 30.
M impact | EQUITY | Nov 03, 2026, 02:32 PM UTC
Keurig Dr Pepper Reports Quarterly Results
Keurig Dr Pepper reported results for the quarter ended September 30. The supplied body contains no figures.
M impact | EQUITY | Nov 03, 2026, 02:32 PM UTC